Roka Bioscience, a Warren, N.J.-based company focused on developing and commercializing innovative solutions based on molecular technologies for the industrial markets, has secured $47.5m in Series D financing.
The company closed on $27.5m of the Series D round in December 2011 and expects to close on the remaining $20m later this year. Backers include new investor Aisling Capital and existing investors OrbiMed Advisors, New Enterprise Associates, and TPG Biotech.
Roka intends to use the funding to commercialize its Atlas™ System and ongoing assay development. The Atlas™ System is an innovative fully automated molecular instrument for the detection of food pathogens in food and environmental samples. It will initially focus on Listeria and Salmonella Detection Assays, with additional assays currently in development.
In conjunction with the funding, Josh Bilenker, M.D., Partner at Aisling Capital, will join the company’s Board of Directors, which is led by CEO and President Paul Thomas.
FinSMEs
09/01/2012
Related News
28/07/2011: Roka Bioscience Completes $20M Series C Equity Financing